

Oncology Today with Dr Neil Love: Novel Agents and Strategies in the Treatment of Ovarian Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. The Phase III SORAYA study evaluated the efficacy and safety of mirvetuximab soravtansine in which of the following populations of patients with ovarian cancer?**
 - Newly diagnosed platinum-sensitive disease
 - Newly diagnosed platinum-resistant disease
 - Platinum-resistant disease treated with 1 to 3 prior regimens**
 - Platinum-resistant disease without prior PARP inhibition or bevacizumab therapy
- 2. According to Phase III data, which of the following types of adverse events of special interest is most commonly observed in patients receiving mirvetuximab soravtansine for platinum-resistant ovarian cancer?**
 - Dermatologic
 - Neurologic
 - Ocular**
 - Respiratory
- 3. What is the target of the novel antibody-drug conjugate upifitamab rilsodotin, currently under investigation for patients with ovarian cancer?**
 - Folate receptor alpha
 - NaPi2b (sodium-dependent phosphate transport protein 2b)**
 - Tissue factor
 - TROP2
- 4. By which mechanism do tumor treating fields promote tumor cell death?**
 - Altered cell division**
 - Necrosis
 - Detachment from matrix
 - Autophagy
- 5. An ongoing Phase III study based on promising early-phase findings is evaluating tumor treating fields in combination with which of the following therapies for patients with recurrent ovarian cancer?**
 - Paclitaxel**
 - Bevacizumab
 - Olaparib
 - Mirvetuximab soravtansine